Subsequently, the second PD-1 antibody, pembrolizumab, was designated for the treatment of advanced melanoma due to its manageable irAEs and significant improvements in prognosis and fewer treatment-related adverse events than chemotherapy [49]. The gene discussed is PDCD1; the disease is melanoma.